Perspectives: Will OPill Be Affordable To Those Who Need It?; Simufilam For Alzheimer’s May Be Unsafe
Read recent commentaries about pharmaceutical issues.
New England Journal of Medicine:
The New Over-The-Counter Oral Contraceptive Pill — Assessing Financial Barriers To Access
The FDA’s approval of Opill could dramatically improve practical access to family planning. But whether people throughout the country will be able to afford it remains an open question. (Christopher Robertson, J.D., Ph.D., and Anna Braman, B.A., 10/12)
Stat:
Cassava Sciences’ Alzheimer’s Clinical Trials Should Be Halted
The Food and Drug Administration should halt Cassava Sciences’ ongoing clinical trials in Alzheimer’s disease. That, and other thoughts on the fallout from the City University of New York investigation that raised serious doubts about the science underpinning the company’s experimental drug simufilam. (Adam Feuerstein, 10/17)
New England Journal of Medicine:
Wedding Websites, Free Speech, And Adverse Drug Effects
The principles underlying the U.S. Supreme Court decision in 303 Creative L.L.C. v. Elenis could have far-reaching implications, possibly affecting our ability to learn about side effects of drugs. (Jerry Avorn, 10/14)
